XR5000: XEN discontinued development of XR5000 due to lack of efficacy in Phase II trials in patients with glioblastoma, non-small cell lung carcinoma, or ovari

Xenova Group plc (LSE:XEN; XNVA), Slough, U.K.
Product: XR5000

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE